MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, To Explore the Role of the Gut Microbiome To Overc…

MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC ...
eLife

Specialisation of meiotic kinetochores revealed through a synthetic SAC strategy

The authors present convincing data to validate abscisic acid-induced dimerisation to induce a synthetic spindle assembly checkpoint (SAC) arrest that will be of particular importance to analyse ...

Maharashtra CET Cell launches district outreach to boost awareness of entrance exams

For the first time, the Maharashtra Common Entrance Test CET Cell has launched a series of outreach programmes to create ...

Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape

GTB-5550 represents GT Biopharma's third NK cell engager advancing toward clinical development, targeting B7-H3, a protein prevalent across breast, lung, ovarian, pancreatic, prostate, bladder, and ...

(PMZN) GT Biopharma Announces IND Submission for GTB-5550 TriKE(R), a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GT Biopharma, Inc. (the "Company") (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE(R) natural killer (NK ...
TMCnet

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative ...

Textbooks Challenged: Scientists Discover New Mechanism of Cell Division

Scientists have uncovered a new way embryonic cells divide when conventional mechanisms fail. Cell division underpins all ...